The estimated Net Worth of Pam P. Cheng is at least $880 Tysiąc dollars as of 21 May 2018. Ms. Cheng owns over 39,215 units of Codexis stock worth over $160,303 and over the last 10 years she sold CDXS stock worth over $549,794. In addition, she makes $169,989 as Independent Director at Codexis.
Pam has made over 1 trades of the Codexis stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 39,215 units of CDXS stock worth $549,794 on 21 May 2018.
The largest trade she's ever made was selling 39,215 units of Codexis stock on 21 May 2018 worth over $549,794. On average, Pam trades about 5,602 units every 0 days since 2014. As of 21 May 2018 she still owns at least 58,719 units of Codexis stock.
You can see the complete history of Ms. Cheng stock trades at the bottom of the page.
Pam P. Cheng is appointed as Independent Director of the Company. Ms. Cheng brings to our board of directors experience in pharmaceutical manufacturing and conducting business in Asia, as well as senior management and financial operations experience. Ms. Cheng has served as the Executive Vice President, Operations and IT for AstraZeneca plc, a publicly-traded multinational pharmaceutical and biologics company, since June 2015. Previously, Ms. Cheng was a 17-year veteran of Merck and most recently served as President of MSD China, Merck’s subsidiary in China. Prior to serving as President of MSD China, Ms. Cheng served as Senior Vice President, Global Supply Chain Management for Merck in New Jersey, with overall end-to-end supply chain oversight for its human health, vaccines, and consumer care businesses globally. Before Merck, Ms. Cheng held operational roles at GAF Chemicals and UOP/Union Carbide. Ms. Cheng received an M.B.A. in Marketing from Pace University in New York and her Bachelor and Masters of Chemical Engineering from the Stevens Institute of Technology in New Jersey. She has also earned Six Sigma Executive Belt Certification. Ms. Cheng’s term of directorship will expire at the Annual Meeting.
As the Independent Director of Codexis, the total compensation of Pam Cheng at Codexis is $169,989. There are 6 executives at Codexis getting paid more, with John Nicols having the highest compensation of $3,408,030.
Pam Cheng is 49, she's been the Independent Director of Codexis since 2014. There are 12 older and no younger executives at Codexis. The oldest executive at Codexis Inc. is Thomas Baruch, 81, who is the Independent Director.
Pam's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Over the last 15 years, insiders at Codexis have traded over $34,923,852 worth of Codexis stock and bought 399,963 units worth $1,488,111 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Ventures Life Sciences 2000... oraz John J Nicols. On average, Codexis executives and independent directors trade stock every 32 days with the average trade being worth of $153,997. The most recent stock trade was executed by Byron L Dorgan on 15 November 2023, trading 20,000 units of CDXS stock currently worth $42,200.
codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop
Codexis executives and other stock owners filed with the SEC include: